Active vaccine safety surveillance of seasonal influenza vaccination via a scalable, integrated system in Western Australian pharmacies: a prospective cohort study

Sandra Salter,1 Gurkamal Singh,1 Lisa Nissen,2 Kevin Trentino,3 Kevin Murray,3 Kenneth Lee,1,3 Benjamin Kop,1 Ian Peters,4 Alan Leeb4

ABSTRACT

Objectives We integrated an established participant-centred active vaccine safety surveillance system with a cloud-based pharmacy immunisation-recording program in order to measure adverse events following immunisation (AEFI) reported via the new surveillance system in pharmacies, compared with AEFI reported via an existing surveillance system in non-pharmacy sites (general practice and other clinics).

Design A prospective cohort study.

Participants and setting Individuals >10 years receiving influenza immunisations from 22 pharmacies and 90 non-pharmacy (general practice and other clinic) sites between March and October 2020 in Western Australia. Active vaccine safety surveillance was conducted using short message service and smartphone technology, via an opt-out system.

Outcome measures Multivariable logistic regression was used to assess the primary outcome: differences in proportions of AEFI between participants immunised in pharmacies compared with non-pharmacy sites, adjusting for confounders of age, sex and influenza vaccine brand. A subgroup analysis of participants over 65 years was also performed.

Results Of 101 440 participants (6992 from pharmacies; 94 448 from non-pharmacy sites), 77 498 (76.4%) responded: 96.1% (n=74 448) within 24 hours. Overall, 4.8% (n=247) pharmacy participants reported any AEFI, compared with 6% (n=4356) non-pharmacy participants (adjusted OR: 0.87, 95% CI: 0.76 to 0.99; p=0.039). Similar proportions of AEFI were reported in pharmacy (5.8%; n=31) and non-pharmacy participants (6; n=1617) aged over 65 years (adjusted OR: 0.94; 95% CI: 0.65 to 1.35; p=0.725). The most common AEFI in pharmacy were: pain (2%; n=104), tiredness (1.9%; n=95) and headache (1.7%; n=88); and in non-pharmacy sites: pain (2.3%; n=1660), tiredness (1.9%; n=1362) and swelling (1.5%; n=1121).

Conclusions High and rapid response rates demonstrate good participant engagement with active surveillance in both pharmacy and non-pharmacy participants. Significantly fewer AEFI were reported after pharmacist immunisations compared with non-pharmacy immunisations, with no difference in older adults, may suggest different cohorts attend pharmacy versus non-pharmacy immunisers. The integrated pharmacy system is rapidly scalable across Australia with global potential.

INTRODUCTION

Pharmacists have an established role in vaccination services. In Australia, this role has expanded from vaccinating adults with influenza vaccine in the Queensland Pharmacy Immunisation Pilot in 2013, to encompass multiple age groups and vaccines across Australia. Pharmacists in Australia administer vaccines without a prescription to patients in community pharmacies, and in locations outside pharmacies (such as aged care facilities, schools and COVID-19 vaccination hubs). Depending on legislative
requirements for each state and territory, they can administer influenza vaccines to persons aged 10 years and over; diphtheria-tetanus-acellular pertussis, inactivated poliovirus, measles-mumps-rubella, cholera, Haemophilus influenzae type B, hepatitis A, pneumococcal and meningococcal ACWY vaccines to persons aged 15–16 years and over; and COVID-19 vaccines to persons aged 18 years and over.5–7

Serious reactions to vaccines can and do occur. In 2010, a surge in serious adverse events following immunisation (AEFI) in Western Australian children following vaccination with the seasonal trivalent influenza vaccine led to a Ministerial review, evaluation of the processes for AEFI reporting and investigation of the impact of the 2010 reactions on immunisation rates.10–12 This prompted fundamental change in vaccine safety surveillance in Western Australia and Australia. In 2011, the Western Australia (WA) Department of Health launched the (passive) WA Vaccine Safety Surveillance system.13 Simultaneously, SmartVax, an automated active surveillance program that employs short message service (SMS) and smartphone technology was developed and implemented in general practice.14 AusVaxSafety was also established by the National Centre for Immunisation Research and Surveillance to monitor AEFI with influenza vaccines in children, and now operates as a multicomponent system that includes active vaccine safety surveillance for all vaccines, the Adverse Events Following Immunisation – Clinical Assessment Network, and vaccine safety in primary healthcare data.15–17 Importantly, AusVaxSafety uses technology-based surveillance tools, including SmartVax (established in approximately 350 general practice and clinic sites across Australia), to directly contact patients after immunisation in a participant-centred active vaccine safety surveillance approach.15,18

This infrastructure precedes pharmacist vaccinations in Australia, yet despite mandated vaccine safety surveillance responsibilities for pharmacists and their planned role in COVID-19 vaccination programmes,19–25 there are no vaccine safety surveillance tools in use in Australian pharmacies, and no formal systems for post-vaccination follow-up once patients have left the pharmacy. Furthermore, there are no prospective, patient-centred AEFI studies from pharmacy, and no information on differences in AEFI rates between immunisation providers. Therefore it is crucial to link pharmacy with established infrastructure to ensure patients immunised by pharmacists are followed up, and that those AEFI reports are included in national surveillance. A system that uses existing tools, is automated, and linked directly to pharmacy software offers a simple, fail-safe option for surveillance, with little impact on pharmacist workload. MedAdvisor is a global, cloud-based, automated application for pharmacy,14 used widely in Australia. The MedAdvisor PlusOne software platform is used by pharmacists to record immunisation encounters, and automatically reports immunisations to the Australian Immunisation Register (AIR). In order to develop a participant-centred, automated active vaccine surveillance system for pharmacies, suitable for monitoring any vaccine delivered by pharmacists, we integrated SmartVax with MedAdvisor. In this pharmacy pilot we sought to: (1). Measure AEFI reported via the integrated pharmacy system, and compare these with AEFI reported via an existing surveillance system in non-pharmacy sites (general practice and other clinics), during the 2020 influenza immunisation season in WA; and (2). Determine the technical success of the integrated pharmacy system via an audit.

METHODS
Study design, participants and setting
We conducted a prospective cohort study of participants receiving immunisations from pharmacist and non-pharmacist providers in WA between March and October 2020. Participants were consecutive individuals who self-selected to receive an influenza immunisation at any of 112 locations in WA. This included 22 pharmacies recruited for the purposes of this study and 90 non-pharmacy immunisation sites participating in ongoing active surveillance as part of usual practice. The aforementioned 22 pharmacies were recruited for SmartVax integration in March 2020 via: direct email to all WA community pharmacies using the MedAdvisor PlusOne software to record immunisations; promotion through professional newsletters and Facebook pages; and via a media release by The University of Western Australia.26 Site and pharmacist immuniser consent were obtained prior to enrolling each pharmacy into the study. All pharmacists were experienced in using the MedAdvisor PlusOne software. Training on the SmartVax system and the study was provided to all pharmacists prior to data collection. All pharmacies received printed material to inform participants of the study consent process, with an explanatory poster for display in the immunisation consulting room.

Non-pharmacy sites (including general practice, university, community and local government clinics) participating in active surveillance through SmartVax have been previously described.26,27 Pharmacists in WA are authorised to administer influenza vaccines to people 10 years and older, so participants aged ≥10 years were eligible for inclusion in this study. SmartVax was used to actively monitor and record AEFIs between March and October 2020. Immunisations recorded in the MedAdvisor PlusOne software at each pharmacy were automatically batched and sent to SmartVax via a push application programming interface (API) each day. The API was used as a centralised mechanism to submit all records of vaccination encounters recorded across the MedAdvisor cloud application (for participating pharmacies) to the SmartVax server. Immunisation encounters recorded in the non-pharmacy sites were automatically extracted by SmartVax program at each site, each day.
SmartVax sent a series of automated SMS text messages to all participants 3–5 days after immunisation, to enquire if any AEFIs had been experienced. In the case of participants <18 years of age, SMS messages were sent to the recorded mobile phone number for their parent or legal guardian. ‘Yes’ responders received a second SMS to enquire whether medical attendance had been sought, followed by a third SMS with a link to a short survey to identify the nature, duration and severity of all reactions (figure 1). The survey enquired specifically about fever, pain, swelling, tired, irritable, sleep, rash, headache, diarrhoea and ‘other’ AEFI. People who responded ‘No’ to SMS1 did not receive a second or third SMS.

We also performed an audit of the integrated pharmacy system to determine the number of immunisation encounters recorded in the MedAdvisor PlusOne software that were (1) captured in the batch process, (2) made available for SmartVax surveillance and (3) ultimately underwent surveillance.

Variables
The primary outcome of interest was any AEFI. Secondary outcomes included AEFIs resulting in medical attendance, and adverse event profile as reported in the survey (fever, pain, swelling, tired, irritable, sleep, rash, headache, diarrhoea and ‘other’ AEFI). In addition to data collected on adverse events, SmartVax captured information on participant age, sex and influenza vaccine brand. In order to compare adverse events reported by participants immunised in pharmacies to non-pharmacy sites, our exposure variable of interest was immunisation provider.

Data for the analysis were obtained from the SmartVax system, which includes participant demographic data, their responses to SMS messages, and where relevant, survey results.

Statistical methods
Summary statistics for each immunisation location were provided and comparisons between pharmacy and non-pharmacy immunisations were made using the independent samples t-test (or Mann-Whitney test for non-normal data) for continuous variables and $\chi^2$ tests for categorical variables. A comparison of participants reporting adverse events following influenza immunisation was made in unadjusted analysis using a $\chi^2$ test. Logistic regression was used to assess differences in proportions of adverse events between participants immunised in pharmacies.
and participants immunised at non-pharmacy sites, adjusting for confounders of age (as a continuous variable), sex and influenza vaccine brand in a multivariable model. People aged 65 years and over are at higher risk of complications from influenza and are recommended to receive an adjuvanted influenza vaccine. In 2020, a new, quadrivalent vaccine (Fluad Quad (Seqirus)), was used for the first time in the Australian population, therefore we conducted a subgroup analysis of participants in this age group. Only complete records (age, sex and influenza vaccine brand) were included in the analyses. The significance level was set at 0.05.

All statistical analyses were conducted using R (V.3.5.3; The R Foundation for Statistical Computing). Results are reported according to Strengthening the Reporting of Observational Studies in Epidemiology checklist for cohort studies.28

RESULTS
A total 101,849 influenza immunisation encounters were eligible for surveillance between 10 March 2020 and 17 October 2020. Of these, 409 were missing sex, leaving 101,440 complete influenza immunisation encounters for active surveillance (6992 from pharmacies and 94,448 from non-pharmacy sites). A total 5100 (72.9%) pharmacy participants and 72,398 (76.7%) non-pharmacy participants responded to SMS1, providing 77,498 immunisation encounters for analysis (figure 1).

The mean (SD) age of participants was 51.5 (21.02) years and 58.3% (n=45,186) were female. The most common influenza vaccines administered were FluQuadri (Sanofi-Aventis): 27.1% (n=27,491), Fluad Quad (Seqirus): 26.6% (n=26,934) and Afluria Quad (Seqirus): 10.3% (n=10,491). Overall, 96.1% (n=74,448) of responders replied within 24 hours of receiving SMS1, with 98.7% (n=76,485) responding within 72 hours. Of all responders, 5.9% (n=4,603) reported an adverse event following immunisation.

We present the characteristics of participants immunised in table 1.

Participants receiving influenza vaccinations at pharmacies had a lower mean age (46.5 vs 51.9 years; p<0.001), with 10.5% (n=533) aged 65 years and over compared with 37.4% (n=27,042) at non-pharmacy sites. Pharmacists were more likely to administer Afluria Quad (Seqirus) and Fluarix Tetra (GlaxoSmithKline), while non-pharmacist immunisers were more likely to administer Fluad Quad (Seqirus) and FluQuadri (Sanofi-Aventis) (p<0.001). Response times to the first SMS were similar between groups, with a median (IQR) of 13 min (3–72 min) for pharmacy and 14 min (4–70 min) for non-pharmacy vaccinees.

Table 1 Characteristics of influenza immunisation encounters by location

<table>
<thead>
<tr>
<th>Location</th>
<th>Pharmacy (n=5100)</th>
<th>Non-pharmacy (n=72,398)</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sex, female (%)</td>
<td>3016 (59.1)</td>
<td>42,170 (58.2)</td>
<td>0.218</td>
</tr>
<tr>
<td>Age, years (mean (SD))</td>
<td>46.52 (17.02)</td>
<td>51.90 (21.23)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Age, years (minimum, maximum)</td>
<td>10, 99</td>
<td>10, 101</td>
<td></td>
</tr>
<tr>
<td>Age group, years</td>
<td></td>
<td></td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>&lt;18</td>
<td>371 (7.3)</td>
<td>7,314 (10.1)</td>
<td></td>
</tr>
<tr>
<td>18–64</td>
<td>4,196 (82.3)</td>
<td>38,042 (52.5)</td>
<td></td>
</tr>
<tr>
<td>≥65</td>
<td>533 (10.5)</td>
<td>27,042 (37.4)</td>
<td></td>
</tr>
<tr>
<td>Vaccine brand (%)</td>
<td></td>
<td></td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Afluria Quad</td>
<td>1,974 (38.7)</td>
<td>8,517 (11.8)</td>
<td></td>
</tr>
<tr>
<td>Fluad Quad</td>
<td>514 (10.1)</td>
<td>26,420 (36.5)</td>
<td></td>
</tr>
<tr>
<td>Fluarix Tetra</td>
<td>1,119 (21.9)</td>
<td>6,682 (9.5)</td>
<td></td>
</tr>
<tr>
<td>FluQuadri</td>
<td>914 (17.9)</td>
<td>26,578 (36.7)</td>
<td></td>
</tr>
<tr>
<td>Fluzone High-Dose</td>
<td>0 (0)</td>
<td>2 (0)</td>
<td></td>
</tr>
<tr>
<td>Influvac Tetra</td>
<td>567 (11.1)</td>
<td>1,416 (2)</td>
<td></td>
</tr>
<tr>
<td>Vaxigrip Tetra</td>
<td>12 (0.2)</td>
<td>2,600 (3.6)</td>
<td></td>
</tr>
<tr>
<td>SMS response time, minutes (median (IQR))</td>
<td>13 (3 to 72)</td>
<td>14 (4 to 70)</td>
<td>0.006</td>
</tr>
<tr>
<td>Responses received to SMS1 within 24 hours (%)</td>
<td>49,399 (96.8)</td>
<td>69,549 (96.1)</td>
<td>0.006</td>
</tr>
</tbody>
</table>

Values are count (proportion), mean (SD) or median (IQR) as indicated. P values are calculated from the χ² test for categorical variables and the independent samples t-test for continuous variables.

*The p value for SMS response time was calculated using the Mann-Whitney Wilcoxon Test.

SMS, short message service.
Rate of any adverse event
The unadjusted proportion of any adverse event differed significantly between participants immunised at pharmacies and those immunised elsewhere. Of those immunised at pharmacies, 4.8% (n=247) reported an adverse event, compared with 6% (n=4356) for those immunised at non-pharmacy sites (unadjusted OR=0.80; 95% CI: 0.70 to 0.91; p=0.001). After adjusting for age, sex and vaccine brand, participants immunised at pharmacies reported fewer adverse events, compared with participants immunised in non-pharmacy sites (OR=0.87; 95% CI: 0.76 to 0.99; p=0.039).

Adverse events resulting in medical attendance
Participants reporting any adverse event were sent a second SMS asking if they visited a doctor, medical centre, after-hours service or hospital emergency department as a result of their vaccination reaction. We excluded 646 (0.8%) encounters from this analysis, as they did not respond to the second SMS.

Of participants immunised at pharmacies, 0.1% (n=4) reported seeking medical care following an adverse event compared with 0.3% (n=182) of participants immunised at non-pharmacy sites (p=0.021). After adjusting for age, sex and vaccine brand, participants immunised at pharmacies reported fewer adverse events for which medical attendance was sought, compared with participants immunised at non-pharmacy sites (OR=0.35; 95% CI: 0.13 to 0.97; p=0.042).

Adverse event profile
The most common adverse events reported after immunisation in pharmacies were pain (2%; n=104), tiredness (1.9%; n=95) and headache (1.7%; n=88). The most common adverse events reported after immunisation in non-pharmacy sites were pain (2.3%; n=1660), tiredness (1.9%; n=1362) and swelling (1.5%; n=1121) (figure 2).

A total of 1.4% (n=68) pharmacy and 1.2% (n=778) non-pharmacy participants selected ‘other’ AEFI, and included a text description of the reaction. The majority of these reactions were described as aches, dizziness, muscle and joint pain, cold symptoms, sore throat and nausea (online supplemental tables 1 and 2).

Figure 3 presents ORs for adverse event profile after adjusting for age, sex and vaccine brand, comparing participants immunised at pharmacies to those immunised at non-pharmacy sites.

65 years and over subanalysis
Of participants aged 65 years and over, 5.8% (n=31) immunised at pharmacies reported any adverse event compared with 6% (n=1617) for those immunised at non-pharmacy sites (OR=0.97; 95% CI: 0.67 to 1.40; p=0.875). After adjusting for age, sex and vaccine brand, participants immunised at pharmacies reported similar proportions of any adverse events when compared with participants immunised at non-pharmacy sites (OR=0.94; 95% CI: 0.65 to 1.35; p=0.725). No participants 65 years and over who were immunised at pharmacies reported seeking medical care following an adverse event, compared with 0.3% (n=72) of participants immunised at non-pharmacy sites.

Audit of the integrated pharmacy system
Of 11008 immunisations given in the pharmacies, 10% (n=1106) chose not to participate in surveillance, and 71% (n=7821) were captured in the API batch process. Of these, 95.6% (n=7475) were available for SmartVax surveillance and 92.4% (n=7230) were sent SMS1. We identified in July 2020 that 20.1% (n=2081) records for participants without a recorded sex had not transferred via the API. This was rectified and subsequently 100% of records (including records without sex) were successfully transferred via the API (figure 4).

DISCUSSION
Active surveillance systems, particularly those that integrate new technologies with current vaccine surveillance systems,29 30 are vital to maintain public health and confidence in vaccination, and are directly applicable to the current global vaccination campaign against COVID-19. To the best of our knowledge, this study is the first to
implement and evaluate a system for active surveillance of AEFI in pharmacies.

Through integration of established active vaccine surveillance and cloud-based pharmacy software systems, we developed a robust, rapidly scalable, automated, user-friendly, large scale AEFI monitoring system. While both pharmacy and non-pharmacy sites used the same SmartVax tool to monitor AEFI, only pharmacies made use of the integrated system: non-pharmacy sites use SmartVax as a locally installed software program, whereas the integrated system used cloud technology, and therefore has the advantage of scalability. There was a high (73%) and rapid response to active surveillance following influenza immunisation in pharmacies (median 13 min; 96% within 24 hours); similar to responses observed in non-pharmacy sites, both in this study and previously. While the profile of adverse events reported after pharmacy-based immunisations was similar to that reported after immunisation in non-pharmacy sites, there were significantly fewer adverse events overall reported from participants immunised in pharmacies compared with those immunised in non-pharmacy sites, including general practice and other clinics. After adjusting for age, sex and vaccine brand this difference was still significant, although clinically small. As participants immunised in pharmacies were significantly younger than those in non-pharmacy sites, it is possible that more complex or sicker participants visited non-pharmacy immunisers. Further our analysis could not be adjusted for underlying comorbidities or social factors such as income (which could influence ability to pay for vaccination in the pharmacy). However, there was no difference in overall adverse events observed in our subanalysis of the over 65 years age group, whom we might expect to have more comorbidities or be sicker. Notably, a surge in demand for early influenza vaccination in 2020, means we did not capture all participants immunised in participating pharmacies, as our integrated system was activated a month after pharmacy vaccinations began. This could have included sicker patients of any age, as they may seek immunisation as early as possible in the season. The relationship with the immuniser, anticipation of AEFI or sense of obligation to report even minor reactions may be different for people attending pharmacies and non-pharmacy sites, but we did not measure this. Furthermore, each site can and does immunise patients opportunistically. Such immunisation may, by default, affect the cohort attending and their perception of AEFIs: people opportunistically immunised in non-pharmacy sites (including general practice) may perceive themselves to be sicker or may feel obliged to report AEFIs to their doctor, although we did not measure the proportion of booked versus opportunistic immunisations, or ask patients directly about their perceptions. Regardless, given response rates and time to respond were similar between groups, the reason for the observed difference and whether it is a true effect remains unclear. Even if the difference is true, it may simply represent different cohorts being immunised in different sites: this in itself is of benefit as it indicates pharmacies may capture a different set of people who may otherwise not seek immunisation. Importantly, engagement with the integrated pharmacy system was observed in 5100 participants (aged 10–99 years) across 22 pharmacies, illustrating that age was not a barrier to pharmacy vaccination, nor the technology used in the system.

This study has the potential to change practice immediately. Most pharmacy vaccinations in Australia are recorded using two cloud-based software platforms, each

Figure 3  Adjusted ORs (95% CI) comparing proportion of adverse events reported following immunisation in pharmacies to non-pharmacy sites.

<table>
<thead>
<tr>
<th>Reported Outcome</th>
<th>Adjusted Odds Ratio (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Any adverse event</td>
<td>0.86 (0.75, 0.99)</td>
</tr>
<tr>
<td>Fever</td>
<td>0.74 (0.51, 1.07)</td>
</tr>
<tr>
<td>Pain</td>
<td>0.98 (0.79, 1.21)</td>
</tr>
<tr>
<td>Swelling</td>
<td>0.78 (0.59, 1.04)</td>
</tr>
<tr>
<td>Tired</td>
<td>1.04 (0.83, 1.3)</td>
</tr>
<tr>
<td>Irritable</td>
<td>0.82 (0.49, 1.36)</td>
</tr>
<tr>
<td>Sleep</td>
<td>0.69 (0.44, 1.08)</td>
</tr>
<tr>
<td>Rash</td>
<td>0.83 (0.39, 1.75)</td>
</tr>
<tr>
<td>Headache</td>
<td>1.29 (1.03, 1.63)</td>
</tr>
<tr>
<td>Vomiting</td>
<td>0.55 (0.2, 1.55)</td>
</tr>
<tr>
<td>Diarrhoea</td>
<td>0.64 (0.25, 1.62)</td>
</tr>
<tr>
<td>Other</td>
<td>1.24 (0.96, 1.61)</td>
</tr>
<tr>
<td>Medical attendance</td>
<td>0.35 (0.12, 0.96)</td>
</tr>
</tbody>
</table>
Figure 4  Audit of data flow in the integrated pharmacy active vaccine safety surveillance system. *SmartVax automatically monitors all encounters three business days after immunisation. Therefore encounters entered to MedAdvisor PlusOne more than three business days after immunisation did not receive SMS1. This scenario occurred in pharmacies with a paper-to-electronic recording system. These encounters still transferred via the API but did not meet criteria for automatic surveillance. †Unseasonably high demand for influenza vaccination early in the season resulted in low numbers of immunisations after July. API, application programming interface; SMS, short message service.
of which automatically reports to the AIR.31 Previously, there were no active vaccine safety surveillance systems and no mechanism to identify AEFI once patients left the pharmacy. Through this study, active vaccine safety surveillance is now scalable to thousands of pharmacies in Australia and can monitor patients out of reach of other surveillance networks. Furthermore, there is potential for global application given the cloud-based pharmacy software integrated in this study, MedAdvisor, has an international presence. This may be particularly useful for pharmacies in countries where there does not appear to be published evidence of ongoing active surveillance systems, for example, the UK.32

Significant economies of scale are achieved through the pharmacy integration: technical support (including program updates and modifications to surveillance parameters), or addition of surveillance fields (such as medication lists or demographic variables), can be achieved efficiently in either component of the integrated system and activated in real-time across participating sites. This could offer an advantage over non-pharmacy systems, which currently use locally, installed software. The integrated system can also contribute to research, such as to provide long-term vaccine surveillance data for linkage to national or state based administrative data sets (eg, to enable comparison of actively reported AEFI against long-term outcomes or infection). Connection through the integration to AusVaxSafety, the principal Australian AEFI active surveillance system, means pharmacy AEFI can be included in publicly reported surveillance data, ensuring open and transparent monitoring. In context of high social media-led disinformation campaigns about vaccine safety,33 open reporting promotes public confidence in the vaccine and the surveillance system, and can mitigate anti-vaccination campaigns.12 While provider recommendations drive immunisation,34 public and provider belief that regulatory systems are robust remain critical to uptake and high immunisation rates required for herd immunity.35

Rapid engagement of a trained immunisation workforce with access to active vaccine safety surveillance will be critical for COVID-19 vaccine deployment. Pharmacists have been recognised as qualified immunisers in many countries for more than 10 years.2 Two systematic reviews have demonstrated pharmacists increase vaccination coverage when compared with traditional (non-pharmacist) providers alone.36 37 Several factors specific to pharmacies including convenience, accessibility, extended opening hours and the ability to obtain a vaccination without prior appointment have been shown to increase immunisation rates across the world and it is likely pharmacies capture patients who would otherwise not get immunised.12 36 37 In the Australian context, cost is an interesting factor. Most pharmacy vaccination services are not remunerated by Australian state or federal governments and patients pay the full cost for the vaccine as well as any service fees. By contrast, vaccination service fees in general practice and non-pharmacy clinics are subsidised either partially or fully by the federal government, and vaccines are provided free for all eligible patients under the National Immunisation Program (NIP), including for babies, children and adults. Since 2019, a government programme to expand access to influenza vaccines has enabled participating pharmacies in WA and the Australian Capital Territory to administer influenza vaccinations to persons aged 65 years and older, under NIP. Pharmacies in this programme receive free vaccine but no service fee, and may choose to charge a service fee to the patient,7 which means for the patients of those pharmacies aged over 65, it is still more expensive to be vaccinated in the pharmacy than a non-pharmacy site. Not all pharmacies in our study participate in the NIP programme, and we did not distinguish patients aged over 65 in the pharmacy subgroup who may have been eligible for an NIP funded vaccination, as this detail was not available.

A key strength of this study was our technical audit, to confirm immunisation records transferred as expected using the integrated pharmacy system. To the best of our knowledge this is the only audit of data flow in an active surveillance system. We identified three key issues. First, the API did not identify records without sex recorded, and as a result, 21% of pharmacy immunisations were not automatically monitored in the first half of this study. This issue was identified, the system was updated and all records subsequently transferred. Future iterations of the integrated system should enforce recording of all patient data during the consent process. Second, a small proportion of pharmacists used a paper-based system to record vaccination encounters, and subsequently transposed those records to the electronic system. This may have been a stop-gap measure during the unprecedented demand period of early COVID-19 activity, or it may represent usual practice. Records transferred more than three business days after immunisation were not automatically monitored, and the reason for the paper system was not elucidated. Nonetheless, this represents an area where pharmacists must improve their practice: from 2021 it is mandatory for all vaccination providers to report vaccines given to the AIR,38 and timely record keeping is essential for this. Third, 3% of participants did not have a valid mobile phone number recorded and were not monitored. Attention should be given to identify whether participants own a mobile phone, and if so, to accuracy in data entry. Access to technology may also pose an issue for a wider population as the integrated pharmacy system requires internet connectivity for the pharmacist and mobile network connectivity for the patient. Beyond the audit, approximately 10% of pharmacy participants declined to participate in the study and were not sent SMS1. This may have been a feature of not wishing to participate in a research project, rather than wishing to avoid monitoring. It is not possible to predict whether participants would choose to participate in monitoring under real-world conditions, or whether different vaccines could affect interest in receiving monitoring.
CONCLUSION

We are on the cusp of a new period in immunisation. The crucial next step is to leverage proven technology to enable broad scale deployment of vaccines, with a trained workforce enabled with vaccine safety surveillance systems. We have developed an integrated active vaccine safety surveillance system that is scalable to thousands of pharmacies in Australia and potentially globally. Lower proportions of adverse events following influenza immunisation in pharmacies compared with non-pharmacy sites demonstrates pharmacies are a safe destination for immunisation, and may capture people who might otherwise not get vaccinated. With an integrated system that facilitates both reporting of the immunisation to the AIR, as well as links to national vaccine safety surveillance, pharmacists in Australia can contribute actively and safely to all immunisation programmes.

Contributors SS conceptualised, designed and supervised the study, raised funding for the study, assisted with data collection and analysis, interpreted the results, wrote the draft versions and prepared the final version of the manuscript. GS performed the literature review, assisted with data collection and interpretation of the results and reviewed the manuscript. LN raised funding for the study, assisted with study design and recruitment, interpreted the results and reviewed the manuscript. KT assisted with data collection, verified the underlying data, performed data analysis, interpreted the results, prepared all charts, wrote part of the draft versions and reviewed the manuscript. KM assisted with data collection, verified the underlying data, assisted with data analysis, interpreted the results and reviewed the manuscript. AL assisted with study design, raised funding and reviewed the manuscript. BK performed the literature review, assisted with data collection and interpretation of the results and reviewed the manuscript. IP provided intellectual and technical input, provided access to active surveillance, assisted with study supervision, data collection and analysis, interpreted the results and reviewed the manuscript. AL provided intellectual input, provided access to active surveillance, assisted with study supervision, data collection and analysis, interpreted the results and reviewed the manuscript. All authors have read and approved the final version of the manuscript.

Funding The research was supported by a research grant provided by the J M O’Hara Research Fund of the Pharmaceutical Society of Western Australia. Grant number not applicable.

Competing interests AL and IP are Directors of SmartVax Data, of which SmartVax is a subsidiary. IP has previously received funding from SmartVax Data for database development separate to this study.

Patient consent for publication Not required.

Ethics approval Approval to conduct this research was obtained from the Human Research Ethics Committee of The University of Western Australia.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement Data are available upon reasonable request. Individual participant data that underlie the results reported in this article, after de-identification (text, tables, figures and supplemental material) are available upon reasonable request. Proposals for data should be directed to Sandra Salter via ORCID: https://orcid.org/0000-0002-5840-6797. To gain access to data, users will need to sign a data access agreement. Reuse is permitted under the following conditions: meta-analyses of adverse events following immunisation in pharmacies.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

ORCID iDs
Sandra Salter http://orcid.org/0000-0002-5840-6797
Lisa Nissen http://orcid.org/0000-0001-5826-4605
Kevin Trentino http://orcid.org/0000-0002-8768-9263
Kevin Murray http://orcid.org/0000-0002-8556-6046
Kenneth Lee http://orcid.org/0000-0003-3022-4868

REFERENCES
3 Nissen LM, Glass BD, ETL, L Queensland pharmacist immunisation pilot (QPIP) phase 1 pharmacist vaccination-influenza final report.
10


Open access


24 pdf [Accessed 02 Dec 2020].


